Cardiorenal syndrome: New perspectives

Circulation

Volumn 121, Issue 23, 2010, Pages 2592-2600

  Bock, Jeremy S ^a   Gottlieb, Stephen S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ERYTHROPOIETIN;

ANEMIA; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CENTRAL VENOUS PRESSURE; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HUMAN; INTRAABDOMINAL VENOUS PRESSURE; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY DYSFUNCTION; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYNDROME; VENOUS PRESSURE;

HEART FAILURE; HUMANS; KIDNEY DISEASES; SYNDROME;

EID: 77953776647     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.886473     Document Type: Review

References (78)

1. NHLBI Working Group. Cardio-renal connections in heart failure and cardiovascular disease. National Heart, Lung, and Blood Institute Web site. http://www.nhlbi.nih.gov/meetings/workshops/cardiorenal-hf-hd.htm. Accessed October 10, 2009.
2. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med. 2008;34:957-962.
3. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP, for the ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-216.
4. McAlister FA, Ezekowtiz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2003;109:1004-1009.
5. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Char-lesworth A, Hampton JR, van Veldhuisen DJ. Renal function, neuro-hormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210.
6. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-67. (Pubitemid 38045917)
7. Gottlieb SS, Abraham WT, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136-141.
8. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12.
9. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(suppl): S16-S23.
10. Tonelli M, Wiebe N, Culleton, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: a systemic review. J Am Soc Nephrol. 2006;17:2034-2047.
11. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995;47:884-890.
12. Wali RK, Wang GS, Gottlieb SS, Bellumkonda L, Hansalia R, Ramos E, Drachenberg C, Papadimitriou J, Brisco MA, Blahut S, Fink JC, Fisher ML, Bartlett St, Weir MR. Effect of kidney transplantation on left ventricular systolic function and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol. 2005;451051-451060
13. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996;27:347-354.
14. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996;11:1277-1285.
15. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51:1268-1274.
16. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999;138:285-290.
17. Mullens W, Abrahams Z, Skouri HN, Francis GS, Taylor DO, Starling RC, Paganini E, Tang WHW. Elevated intra-abdominal pressure in acute decompensated heart failure. J Am Coll Cardiol. 2008;51:300-306.
18. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH. Importance of venous congestion for worsening renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-596.
19. Heidenhain R. Hermann's Handbuch der Physiologie, Volume 5. Leipzig, Germany: F.C.W. Vogel; 1883;I:317.
20. Winton FR. The influence of venous pressure on the isolated mammalian kidney. J Physiol. 1931;72:49-61.
21. Blake WD, Wegria R, Keating RP, Ward HP. Effect of increased renal venous pressure on renal function. Am J Physiol. 1949;157:1-13.
22. Bradley SE, Bradley GP. The effect of increased intra-abdominal pressure on renal function in man. J Clin Invest. 1947;26:1010-1015.
23. Doty JM, Saggi BH, Sugerman HJ, Fakhry I, Gehr T, Sica D, Sugerman HJ. Effect of increased renal venous pressure on renal function. J Trauma. 1999;47:1000-1003.
24. Meldrum DR, Moore FA, Moore EE, Franciose RJ, Sauaia A, Burch JM. Prospective characterization and selective management of the abdominal compartment syndrome. Am J Surg. 1997;45:667-673.
25. Malbrain ML, Cheatham ML, Kirkpatrick, Sugrue M, Parr M, De Waele J, Balogh Z, Leppäniemi A, Olvera C, Ivatury R, D'Amours S, Wendon J, Hillman K, Johansson K, Kolkman K, Wilmer A. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. Intensive Care Med. 2006;32: 1722-1732.
26. Doty JM, Saggi BH, Blocher CR, Fakhry I, Gehr T, Sica D, Sugerman HJ. Effects of increased renal parenchymal pressure on renal function. J Trauma. 2000;48:874-877.
27. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53:582-588.
28. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001;345:574-581.
29. Maeder MT, Holst DP, Kaye DM. Tricuspid regurgitation contributes to renal dysfunction in patients with heart failure. J Card Fail. 2008;10: 824-830.
30. Laederach K, Weidmann P. Plasma and urinary catecholamines as related to renal function in man. Kidney Int. 1987;31:107-111.
31. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373:1275-1281.
32. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932-934.
33. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angioten-sin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
34. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M. Hemodynamic and neurohormonal effects of the angio-tensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;35:714-721.
35. St John Sutton M, Pfeffer MA, Moye L, Plappert T, Rouleau JL, Lamas G, Rouleau J, Parker JO, Arnold MO, Sussex B, Braunwald E. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation. 1997;96:3294-3299.
36. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int. 2002;82:S12-S22.
37. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of the renin-an-giotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 2005;suppl:S57-S65.
38. Griendling KK, Minieri CA, Ollerensaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
39. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol. 2003;41:2164-2171.
40. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int. 2003;63:179-185.
41. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, Utsumi H, Takeshita A. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res. 2000;87:392-398.
42. Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T. Angiotensin II and oxidative stress in Dahl salt-sensitive rat with heart failure. Hypertension. 2002;40:834-839.
43. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, Tatge H, Drexler H. Comparative effect of ACE inhibition and angiotensin type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dis-mutase. Circulation. 2001;103:799-805.
44. McClellen W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20: 1501-1510.
45. Young JB, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O'Connor CM, She L, Sun JL, Yancy CW, Fonarow GC, for the OPTIMIZE-HF Investigators and Coordinators. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol. 2008;101:223-230.
46. George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T, Sheps D, Keren G. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med. 2005;165:1304-1309.
47. Jie KE, Verhaar MC, Cramer MJ, van der Putten K, Gaillard CA, Doevendans PA, Koomans HA, Joles JA, Braam B. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol. 2006;291:F932-F944.
48. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003;100:4802-4806.
49. Vesey DA, Cheung C, Pat B, Endre Z, Gobé G, Johnson DW. Erythro-poietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004;19:348-355.
50. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-1744.
51. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004;66:1131-1138.
52. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, for the CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
53. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure, J Am Coll Cardiol. 1983;1:1385-1390.
54. Konstam MA, Gheorghiade M, Burnett JC Jr., Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297: 1319-1331.
55. Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori M. Plasma adenosine levels increase in patients with chronic heart failure. Circulation. 1997;95:1363-1365.
56. 1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348-1353.
57. 1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail. 2007;13:609-617.
58. Boerrigter G, Lapp H, Burnett JC. Modulation of cGMP in heart failure: a new therapeutic paradigm. Handb Exp Pharmacol. 2009;191:485-506.
59. Tessone A, Gottlieb S, Barbash IM, Garty M, Porath A, Tenenbaum A, Hod H, Boyko V, Mandelzweig L, Behar S, Leor J. Underuse of standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency. Cardiology. 2007;108:193-199.
60. Echemann M, Zannad F, Briancon S, Juillière Y, Mertès PM, Virion JM, Villemot JP. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. Am Heart J. 2000;139:624-631.
61. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992;70:479-487.
62. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759-1764.
63. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res. 1990;67: 1355-1364.
64. Palermo M, Armanini D, Shackleton CH, Sorba G, Cossu M, Roitman E, Scaroni C, Delitala G. Furosemide and 11 beta-hydroxysteroid dehydro-genase activity in man. Exp Clin Endocrinol Diabetes. 2002;110: 272-276.
65. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA, for the UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decom-pensated heart failure. J Am Coll Cardiol. 2007;49:675-683.
66. Rogers HL, Marshall J, Bock J, Dowling TC, Feller E, Robinson S, Gottlieb SS. A randomized, controlled trial of the renal effects of ultra-filtration as compared to furosemide in patients with acute decom-pensated heart failure. J Card Fail. 2008;4:1-5.
67. Wang DJ, Dowling TC, Meadows D, Ayala T, Marshall J, Minshall S, Greenberg N, Thattassery E, Fisher ML, Rao K, Gottlieb SS. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620-1625.
68. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
69. Hernandez AF, O'Connor CM, Starling RC, Reist CJ, Armstrong PW, Dickstein K, Lorenz TJ, Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JJ, Nieminen M, Rouleau JL, Swedberg K, Califf RM. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J. 2009;157:271-277.
70. Drexler H, Höing S, Faude F, Wollschläger H, Just H. Central and regional vascular hemodynamics following intravenous milrinone in the conscious rat: comparison with dobutamine. J Cardiovasc Pharmacol. 1987;9:563-569. (Pubitemid 17069873)
71. Sato Y, Matsuzawa H, Eguchi S. Comparative study of effects of adrenaline, dobutamine and dopamine on systemic hemodynamics and renal blood flow in patients following open heart surgery. Jpn Circ J. 1982;46:1059-1072.
72. Kurien S, Warfield KT, Wood CM, Miller WL. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide. Am J Cardiol. 2006;98: 1627-1630.
73. Klein L, Massie BM, Leimberger JD, O'Connor CM, Piña IL, Adams KF Jr, Califf RM, Gheorghiade M, for the OPTIME-CHF Investigators. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail. 2008; 1:25-33.
74. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002;4:515-529.
75. Cuffe MS, Califf RM, Adams KF Jr., Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Qu igg R, Silver MA, Gheorghiade M. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-1547. (Pubitemid 34269999)
76. Kellum JA, Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001;29:1526-1531.
77. Ungar A, Fumagalli S, Marini M, Di Serio C, Tarantini F, Boncinelli L, Baldereschi G, Valoti P, La Cava G, Olianti C, Masotti G, Marchionni N. Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure. Crit Care Med. 2004;32: 1125-1129.
78. de Fijter CW, Comans EF, de Vries PM, Oe PL, Roos JC, Smit AJ, Streurman O, Donker AJ. The effect of fenoldopam on renal haemody-namics and natriuresis in chronic renal failure. Neth J Med. 1990;36:267-278.